Vasculitis & polymyalgia rheumatica
Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course
Authors' conclusion
ICI-associated vasculitis are rare, heterogeneous, but can be severe requiring urgent multidisciplinary management with aggressive treatment.
Study context
- Population
- Cancer patients with clinical and/or radiological suspicion and histological evidence of vasculitis after immune checkpoint inhibitor (ICI) exposurecases in ImmunoCancer International Registry (ICIR) registry
- Participants
- 28 patients
- Outcome
- Presentation, treatment and outcome of ICI-associated vasculitis
Methodological detailsregistry study, ImmunoCancer International Registry (ICIR)
- Registry study
- ImmunoCancer International Registry (ICIR)
Main finding
As reported in the abstract
- Median interval from ICI start to vasculitis diagnosis
- 4 months
- Small vessel vasculitis
- 21
- Large vessel vasculitis
- 4
- Medium vessel vasculitis
- 3
- Small vessel: unclassified vasculitis (6 limited cutaneous, 4 systemic)
- 10
- Small vessel: IgA vasculitis
- 5
- Small vessel: cryoglobulinemic vasculitis
- 3
- Small vessel: ANCA+ vasculitis
- 3
- Renal manifestations
- 7 (25%)
- Neurologic manifestations
- 7 (25%)
- Immune glomerulopathies on renal biopsy
- 6
- Fulfilled 2022 ACR/EULAR classification criteria (4 GCA, 2 EGPA, 1 GPA)
- 7 (25%)
- Required systemic corticosteroid
- 90%
- Additional drug given
- 10 (36%)
- Vasculitis complete response
- 22
- Deaths due to vasculitis
- 0
- Rechallenged with immunotherapy
- 9 (32%)
- Relapse after rechallenge
- 1
Observational data: associations, not effects.
Original publication
Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course. Rheumatology (Oxford). Published 23 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →